A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions

This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of SYS6026 at different doses compared to placebo in treating patients with HPV16 or 18-related high-grade cervical squamous intraepithelial lesions (HSIL).

NCT Number	NCT07702656
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	High-grade Cervical Intraepithelial Lesions
Enrollment	175 participants
Start Date	2026-07-10
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-14